Lack of Conventional Acinar Cells in Parotid Salivary Gland of Patient Taking an Anti-PD-L1 Immune Checkpoint Inhibitor by Sarah Pringle, Bert van der Vegt, Xiaoyan Wang, Nico van Bakelen, T. Jeroen N. Hiltermann, Fred K. L. Spijkervet, Arjan Vissink, Frans G. M. Kroese, Hendrika Bootsma

Get full text

Circulating tumor DNA as a biomarker for monitoring early treatment responses of patients with advanced lung adenocarcinoma receiving immune checkpoint inhibitors by Paul van derLeest, Birgitta Hiddinga, Anneke Miedema, Maria L. Aguirre Azpurua, Naomi Rifaela, Arja terElst, Wim Timens, Harry J. M. Groen, Léon C. vanKempen, T. Jeroen N. Hiltermann, Ed Schuuring

Get full text

Prognostic Value of KRAS/TP53 Status for Overall Survival in First-Line Monoimmunotherapy and Chemoimmunotherapy Treated Patients With Nonsquamous NSCLC in the Netherlands: A Brief... by Vincent D. de Jager, MD, Léon C. van Kempen, PhD, Betzabel N. Cajiao Garcia, MSc, T. Jeroen N. Hiltermann, MD, PhD, Anthonie J. van der Wekken, MD, PhD, Ed Schuuring, PhD, Stefan M. Willems, MD, PhD

Get full text

Rising incidence of radiation pneumonitis after adjuvant durvalumab in NSCLC patients treated with concurrent chemoradiotherapy by Rutger H. Stoffers, Anne G.H. Niezink, Olga Chouvalova, Jan F. Ubbels, Marleen Woltman-van Iersel, T. Jeroen N. Hiltermann, Lucie B.M. Hijmering-Kappelle, Gea Douma, Sander M. de Hosson, John W.G. van Putten, Friso T. Zandberg, Lisanne V. van Dijk, Johannes A. Langendijk, Robin Wijsman

Get full text

mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapy by Anastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, Kelly Hoefakker, Bimal Prajapati, Amrita Singh, Annemarie Boerma, Marieke van der Heiden, Sjoukje F. Oosting, Astrid A. M. van der Veldt, T. Jeroen N. Hiltermann, Corine H. GeurtsvanKessel, Anne-Marie C. Dingemans, Egbert F. Smit, Elisabeth G. E. de Vries, John B. A. G. Haanen, Pia Kvistborg, Debbie van Baarle, Debbie van Baarle

Get full text

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer by Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken

Get full text